Dublin, Ireland, February 5th 2008 - AGI Therapeutics plc ("AGI" or the
"Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on
gastrointestinal drug products, today announces that the first patient has been
dosed in its Phase II study of AGI-004 in the treatment of chemotherapy-induced
diarrhoea (CID).
